146 related articles for article (PubMed ID: 30056970)
1. Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Trifan G; Shafi N; Testai FD
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2572-2578. PubMed ID: 30056970
[TBL] [Abstract][Full Text] [Related]
2. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
3. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
4. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
5. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
6. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Reikvam H; Tiu RV
Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
10. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
11. JAK2 mutation-related disease and thrombosis.
Vannucchi AM; Guglielmelli P
Semin Thromb Hemost; 2013 Jul; 39(5):496-506. PubMed ID: 23633193
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
15. Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.
Benmalek R; Mechal H; Zahidi H; Mounaouir K; Arous S; Benouna MEG; Drighil A; Habbal R
J Med Case Rep; 2021 Feb; 15(1):76. PubMed ID: 33593422
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
Abdulkarim K; Samuelsson J; Johansson P; Andréasson B
Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
[TBL] [Abstract][Full Text] [Related]
20. Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals.
Alshemmari S; Almazyad M; Alwehaib A; Ameen R
Cancer Med; 2021 Jan; 10(1):365-371. PubMed ID: 33280271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]